{"id":"bmb-101","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the S1P1 receptor, BMB-101 modulates the sphingosine-1-phosphate (S1P) signaling pathway, which plays a crucial role in immune cell trafficking and lymphocyte egress from lymphoid organs.","oneSentence":"BMB-101 is a small molecule that targets the S1P1 receptor.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:25:13.578Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsing forms of multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07266324","phase":"PHASE2","title":"A 2-Part Study to Assess Efficacy, Safety and Tolerability of BMB-101 for the Treatment of Patients With Prader-Willi Syndrome.","status":"NOT_YET_RECRUITING","sponsor":"Bright Minds Biosciences Pty Ltd","startDate":"2026-01","conditions":"Prader-Willi Syndrome","enrollment":16},{"nctId":"NCT06401538","phase":"PHASE2","title":"BMB-101 in Absence Epilepsy and DEE","status":"RECRUITING","sponsor":"Bright Minds Biosciences Pty Ltd","startDate":"2024-12-05","conditions":"Absence Epilepsy, Jeavons Syndrome, Dravet Syndrome","enrollment":20},{"nctId":"NCT05397041","phase":"PHASE1","title":"A 3-Part Study to Evaluate the Safety, Tolerability, PK, and Food Effect of BMB-101 in Healthy Volunteers","status":"COMPLETED","sponsor":"Bright Minds Biosciences Pty Ltd","startDate":"2022-06-06","conditions":"Healthy","enrollment":81}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BMB-101","genericName":"BMB-101","companyName":"Bright Minds Biosciences Pty Ltd","companyId":"bright-minds-biosciences-pty-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BMB-101 is a small molecule that targets the S1P1 receptor. Used for Relapsing forms of multiple sclerosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}